EUVIMEDOpdag EUVIMED
Open access · CC BY-NC 4.0

Invasive fungal infections are rare in pediatric and young adult autologous hematopoietic stem cell transplant patients

Jane Koo iD, John Huber iD, Priscila Badia iD, Chloe Dunseath, Gabby O'Connor, Stella M Davies iD, Christopher E Dandoy iD

Pediatric Blood & Cancer · 2024

DOI: 10.1002/pbc.31336 ↗

At a glance

Journal article in Pediatric Blood & Cancer, 2024. Written by Jane Koo and 6 co-authors. Institution: Division of Bone Marrow Transplantation and Immune Deficiency, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA. Major MEDLINE topics: Hematopoietic Stem Cell Transplantation, Invasive Fungal Infections, Transplantation, Autologous. 12 references. The full text is freely available (open access, CC BY-NC 4.0).

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Background

Pediatric and young adult patients undergoing autologous hematopoietic stem cell transplant (auto‐HSCT) face a crucial, yet understudied, risk of invasive fungal infections (IFI), especially compared to allogeneic transplants. This gap underscores the need for research in pediatric patients undergoing auto‐HSCT. Our objective was to evaluate the incidence of IFI in pediatric and young adult patients during the first year after auto‐HSCT. Materials and methods We conducted a single‐center retrospective analysis of 150 pediatric and young adult auto‐HSCT patients who underwent transplant from January 2013 to January 2023. We focused on IFI incidence within the first‐year post transplant, using the European Organization for Research and Treatment of Cancer/Mycoses Study Group (EORTC/MSG) criteria for IFI identification.

Results

Among the 150 patients analyzed, with 240 unique transplant episodes, the primary indication was neuroblastoma (37.3%), and micafungin was extensively used for prophylaxis (82.7%). There was an absence of IFI from yeast and mold species, suggesting a low IFI risk in this cohort. The incidence of IFI in pediatric auto‐HSCT recipients receiving micafungin primary antifungal prophylaxis is rare.

Conclusions

The findings advocate for further research to refine prophylaxis guidelines and highlight the need for individualized risk assessment to optimize post‐transplant care.

Subjects

MeSH terms (MEDLINE)

Hematopoietic Stem Cell TransplantationInvasive Fungal InfectionsTransplantation, AutologousHumansMaleRetrospective StudiesFemaleAdolescentChildYoung AdultAdultChild, PreschoolIncidenceAntifungal AgentsFollow-Up StudiesInfantPrognosis

Author keywords

autologous stem cell transplantfungal infectionsinvasive fungal infectionspediatric hematopoietic stem cell transplant

Substances

Antifungal Agents

Authors and institutions

  • Division of Bone Marrow Transplantation and Immune Deficiency, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA.
  • Department of Pediatrics, University of Cincinnati, Cincinnati, Ohio, USA.

ORCID profiles: Jane Koo, John Huber, Priscila Badia, Stella M Davies, Christopher E Dandoy

Cite

APA

Koo, J., Huber, J., Badia, P., Dunseath, C., O'Connor, G., Davies, S. M., & Dandoy, C. E. (2024). Invasive fungal infections are rare in pediatric and young adult autologous hematopoietic stem cell transplant patients. Pediatric Blood & Cancer. https://doi.org/10.1002/pbc.31336

Vancouver

Koo J, Huber J, Badia P, Dunseath C, O'Connor G, Davies SM, et al. Invasive fungal infections are rare in pediatric and young adult autologous hematopoietic stem cell transplant patients. Pediatric Blood & Cancer. 2024. doi:10.1002/pbc.31336

BibTeX
@article{Koo2024,
  author = {Koo, Jane and Huber, John and Badia, Priscila and Dunseath, Chloe and O'Connor, Gabby and Davies, Stella M and Dandoy, Christopher E},
  title = {Invasive fungal infections are rare in pediatric and young adult autologous hematopoietic stem cell transplant patients},
  journal = {Pediatric Blood & Cancer},
  year = {2024},
  doi = {10.1002/pbc.31336}
}
Start for free →